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High protein-induced glomerular hypertrophy is vascular en- mone, insulin-like growth factors (IGFs) and transform-
dothelial growth factor-dependent. ing growth factor  (TGF-) have been studied most
Background. Various growth factors and cytokines have been often [1–3], while vascular endothelial growth factorimplicated in different forms of kidney enlargement such as
(VEGF) has been studied less intensively. VEGF is im-renal growth following induction of diabetes, unilateral ne-
portant for normal growth and survival as well as organphrectomy, and exposure to high protein diet. Vascular endo-
thelial growth factor (VEGF) is essential for normal renal development in neonatal mice [4]. VEGF is essential for
development and plays a role in diabetes-associated renal and normal nephrogenesis and particularly glomerulogenesis
glomerular enlargement.
[5]. Further, VEGF has been implicated in the patho-Methods. To elucidate a possible role for VEGF in high pro-
genesis of early renal dysfunction and glomerular hyper-tein-induced renal/glomerular enlargement, we examined the
effect of a neutralizing VEGF-antibody (VEGF-ab) on kidney trophy in experimental diabetes [6]. In the present study,
weight and glomerular volume in mice fed a high protein diet the involvement of VEGF in high protein induced renal
for up to seven days. and glomerular enlargement was examined in mice usingResults. At day 2 and day 7 of the experimental period, high
a neutralizing murine VEGF-antibody (VEGF-ab). Asprotein diet induced a significant increase in the mean glomeru-
lar volume. This high protein-induced glomerular hypertrophy IGF-I has been implicated in high protein-induced renal
was completely prevented by treatment with VEGF-ab. Kidney growth [3] and a relationship between IGF-I and VEGF
weight was increased significantly only at day 7, and was not has been suggested [7], we also investigated the effect of
influenced by VEGF-ab treatment. High protein diet and/or
VEGF-ab treatment on serum and kidney IGF-I levels.VEGF-ab treatment had no effect on body weight, food intake,
and liver or heart weight.
Conclusions. The administration of a neutralizing VEGF-ab
METHODSin mice fed a high protein diet for one week completely abol-
ished the glomerular hypertrophy seen in placebo-treated ani- Animals
mals on the same diet, without affecting kidney and body
Adult female NMRI mice (Bomholtgaard, Ry, Den-weight. These results demonstrate, to our knowledge for the
mark) with initial body weights of 28.3 0.2 g were usedfirst time, that high protein-induced glomerular hypertrophy
is VEGF-dependent. in the study. The animals were housed 6 to 8 per cage,
had free access to water and chow, and were kept at
constant temperature (21  1C), humidity (55  5%)
Various growth factors and cytokines have been impli- and at a 12-hour light, 12-hour dark cycle (07.00–19.00
cated in different forms of kidney enlargement such as light). The study complied with Danish regulations for
compensatory renal growth following uninephrectomy care and use of laboratory animals.
[1], renal growth induced by diabetes [2] and by high pro-
tein diets [3]. Among these growth factors, growth hor- Study design
The mice were randomly allocated into four groups
of 14 to 16 animals. Mice in groups 1 and 2 were fedKey words: VEGF, kidney growth, glomerular volume, insulin-like
growth factor I, high protein diet, mouse. a custom made synthetic diet containing 20% protein
(Altromin, Lage, Germany) (control (C) groups), while
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Table 1. Mean body weight and food consumption atand group 3 (high protein placebo; PP) were injected with
day 2 and day 7 in control and high protein fed mice
isotype-matched, irrelevant IgG, while mice of groups 2 treated with placebo or VEGF-ab
(control VEGF-ab; CV) and 4 (high protein VEGF-ab;
Day 2 Day 7PV) were injected with VEGF-ab. To evaluate the effect
Body Food Body Foodof high protein at two time points, one half of the animals
weight consumption weight consumption
in each group was sacrificed at day 2, and the remainder g g g g
at day 7. Animals sacrificed on day 2 were injected at day
CP 28.40.4 3.20.2 28.20.8 3.30.1
0 with a bolus of 300 g of either the IgG or VEGF-ab. CV 27.90.6 3.40.3 27.90.5 3.20.1
PP 26.90.7 3.20.2 28.60.3 3.00.1Animals sacrificed on day 7 received the same bolus of
PV 28.50.5 3.20.2 28.30.6 3.20.2either IgG or VEGF-ab at day 0, followed by a dose of
Data are expressed as mean SEM. N 6 to 8 in each group. Abbreviations100 g at days 2, 4 and 6. A full characterization of the
are: CP, control placebo; CV, control VEGF-ab; PP, high protein placebo; PV,
antibody used has been described elsewhere [6, 8]. In high protein VEGF-ab.
brief, Balb/c mice were immunized by three repeated
booster-injections of recombinant human (rh)-VEGF165.
The mice with the highest serum titer to rh-VEGF165 tional area (AG) by light microscopy as previously de-
received an additional injection of rh-VEGF165 and later scribed [12, 13]. The areas were estimated with a 2D-
spleen cells were harvested for production of hybridomas version of the nucleator (CAST, Olympus, Denmark)
to rh-VEGF165. Purified IgG was prepared by Protein A [14] by light microscopy from an average area of 40 to
chromatography from ascites fluid collected from Balb/c 50 glomerular profiles (that is, the capillary tuft omitting
mice that received injections of the cloned hybridomas. the proximal tubular tissue and the Bowmann capsule).
The isotype and light chain composition of the VEGF-ab VG was calculated as:
and the characterization of the neutralizing activity were
VG  /k  (AG)3/2performed as described previously [8].
The VEGF-ab was dissolved in 0.154 mol/L NaCl and where   1.38 is the shape coefficient for spheres (the
injected intraperitoneally using an injection volume of idealized shape of glomeruli) and k  1.1 is a size distri-
0.5 mL. The animals were weighed at day 0, 2 and 7 bution coefficient [15, 16].
and their food consumption was determined every day.
Before sacrificed, the animals were anesthetized with Statistical analysis
pentobarbital (50 mg/kg IP) and non-fasting blood sam- Data were examined for normal distribution and ana-
ples were collected from the retrobulbar plexus using lyzed using the Student unpaired t test if appropriate.
heparinized capillary tubes. The serum samples were For data not following a normal distribution the Mann-
kept at80C for later analysis. Liver, heart, left kidney Whitney rank sum test was used. All data are expressed
and the poles of the right kidney were removed, weighed as mean  SEM, with N indicating the number of mice
and snap frozen in liquid nitrogen. The middle of the studied. Statistics were performed by the statistical pack-
right kidney was fixed in 4% paraformaldehyde for later age SPSS for Windows. P  0.05 was considered statisti-
histological preparation. In the PP group sacrificed at cally significant in a two-tailed test.
day 7, two mice were excluded from the study due to
unexplained massive body weight loss in one animal and
RESULTSdevelopmental renal abnormalities in the other.
Body weight and food consumption
Serum IGF-I and kidney IGF-I determinations Body weight and food intake are given in Table 1. At
Serum IGF-I was measured after extraction using acid- day 2 and day 7, the mean body weights of the different
ethanol as previously described [9, 10]. The intra-assay groups were not significantly changed by high protein
and interassay CV were 5% and 10%, respectively. Tis- diet and/or VEGF-ab treatment (Table 1). Food con-
sue extraction of renal IGF-I was performed according sumption over 24 hours was measured during the study
to D’Ercole, Stiles and Underwood [11] and corrected period on a group basis. At day 0 mean food intake per
for the contribution of entrapped serum IGF-I [12]. mouse was 3.4 0.2 g/24 h with no significant differences
between the groups. At day 2 and day 7, food consump-
Measurement of glomerular volume tion, presented as the mean value of day 0 to 2 and day
The middle part of the right kidney was embedded in 3 to 7, respectively, did not differ significantly in any of
paraffin for light microscopy examination. Two micron- the groups.
thick sections were cut on a rotation microtome and
Kidney weight and glomerular volumestained with periodic acid-Schiff (PAS) and hematoxylin.
In each animal, the mean glomerular tuft volume (VG) At the end of the experimental periods, right kidney
weight was determined. The mean right kidney weightswas determined from the mean glomerular cross-sec-
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Table 2. Mean liver and heart weight at day 2 and day 7 in control
and high protein fed mice treated with placebo or VEGF-ab
Day 2 Day 7
Liver Heart Liver Heart
weight weight weight weight
mg mg mg mg
CP 132543 1164 131636 1172
CV 126431 1183 125444 1183
PP 136976 1224 137835 1224
PV 136978 1143 129547 1173
Data are expressed as mean SEM. N 6 to 8 in each group. Abbreviations
are: CP, control placebo; CV, control VEGF-ab; PP, high protein placebo; PV,
high protein VEGF-ab.
Table 3. Mean kidney and serum IGF-I levels at
day 2 and day 7 in control and high protein fed mice
Fig. 1. Mean right kidney weights at day 2 and day 7 in control mice treated with placebo or VEGF-ab
treated with placebo (CP) or vascular endothelial growth factor-anti-
body (VEGF-ab; group CV) and high protein fed mice treated with Day 2 Day 7
placebo (PP) or VEGF-ab (PV). Values are means  SEM, N  6 to
Kidney Serum Kidney Serum8 in each group. *P  0.01 vs. control groups (CP and CV).
IGF-I IGF-I IGF-I IGF-I
ng/g lg/L ng/g lg/L
CP 738 3929 846 40120
CV 777 38710 854 37222
PP 1447a 46222d 1227b 36336
PV 15210a 49532c 1324a 3848
Data are expressed as mean SEM. N 6 to 8 in each group. Abbreviations
are: CP, control placebo; CV, control VEGF-ab; PP, high protein placebo; PV,
high protein VEGF-ab.
a P  0.0001, b P  0.001, c P  0.01, d P  0.05 vs. control groups (CP and CV)
Mean glomerular volume is given in Figure 2. At day 2
and day 7, mean glomerular volume in the PP group was
significantly increased with 19% and 12%, respectively,
when compared to the CP groups (2.10  0.06 105 m3
and 2.08  0.05 105 m3; P  0.05). VEGF-ab treatment
prevented the high protein-induced increase in mean
glomerular volume both at day 2 and day 7.
Fig. 2. Mean glomerular volume in the right kidney at day 2 and day 7 Mean glomerular volume at day 2 (CP 1.77  0.07
in control mice treated with placebo (CP) or VEGF-ab (CV) and high 105 m3 and CV 1.80  0.04 105 m3) and day 7 (CP
protein fed mice treated with placebo (PP) or VEGF-ab (PV). Values
1.87  0.06 105 m3 and CV 1.88  0.04 105 m3) wasare means  SEM, N  6 to 8 in each group. *P  0.05 vs. CP day 2
and day 7. not statistically different between control groups.
Liver and heart weight
High protein diet and/or VEGF-ab treatment for 2 orare given in Figure 1. Control groups had a similar mean
kidney weight at day 2 (CP 154  10 mg, CV 147  7 days had no significant influence on the weight of liver
and heart (Table 2).7 mg) and day 7 (CP 146  5 mg, CV 149  2 mg). At
day 2, kidney weight was not significantly increased in
Kidney and serum IGF-Ithe high protein groups (PP 169 5 mg, PV 164 2 mg)
when compared to controls (Fig. 1). However, at day 7, Kidney and serum IGF-I levels are given in Table 3.
After two days of high protein diet, kidney IGF-I wasthere was a 22% increase in kidney weight in the PP
group (179  6 mg vs. 146  5 mg, P  0.001) when almost doubled (increase of 97%) both in PP and PV
when compared to the control groups CP and CV, re-compared to CP and a 16% increase in the PV group
(173  6 mg vs. 149  2 mg, P  0.005) when compared spectively. Serum IGF-I was increased to a lesser extent
with 18% (PP vs. CP) and 28% (PV vs. CV). After 7to CV. VEGF-ab treatment had no influence on kid-
ney weight in the control mice nor in the high protein days of high protein diet, kidney IGF-I was still elevated
in the high protein fed groups (45% PP vs. CP and 55%fed mice.
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PV vs. CV) compared to control groups, whereas serum in knockout animals [28, 29] and by postnatal VEGF
inactivation, respectively. Both VEGF and VEGFRs areIGF-I was not different among the four groups. VEGF-ab
treatment had no influence on kidney or serum IGF-I expressed in the glomeruli and tubules of normal rat
kidney [30]. In the glomerulus, VEGF mRNA and pro-levels when compared with the respective control groups.
tein are found in the visceral epithelial cells (podocytes),
whereas VEGFR-2 mRNA and protein are detected in
DISCUSSION
the glomerular endothelial cells [30]. Increased renal ex-
The major new finding of the present study is the spe- pression of VEGF and VEGFRs has been demonstrated
cific inhibitory effect of VEGF-ab treatment on high in experimental diabetes [30], and administration of a
protein-induced glomerular hypertrophy in mice. Treat- neutralizing VEGF-ab in a rat model of type 1 diabetes
ment with VEGF-ab completely normalized the glomer- reduced the diabetes-associated increase in GFR and uri-
ular enlargement induced by high protein diet without nary albumin excretion [6]. These findings suggest a role
affecting body weight, food consumption, liver, heart, or for VEGF in the pathogenesis of diabetic renal changes
kidney weight. This study indicates that VEGF plays a [2, 6, 30]. Interestingly, VEGF-ab administration in dia-
major role in high protein-induced glomerular growth. betic rats abolished glomerular hypertrophy without af-
Increased protein intake is known to cause renal hy- fecting the diabetes-associated renal enlargement [6].
pertrophy and an increase in kidney function [17–20]. This observation is comparable to the effect of VEGF-ab
Kidney size increases linearly with protein intake rate administration obtained in high protein fed mice in the
both in male and female mice [18]. A similar, but less present study. Overall, these results support the conten-
pronounced effect of dietary protein level on glomerular tion that VEGF, besides being essential for normal glo-
filtration rate (GFR) has been shown, however, this ef- merulogenesis, is an important growth factor for glomer-
fect was significant only in male mice [18]. In rats, an ular changes in pathophysiological conditions.
increase in GFR in response to high protein diet has A relationship has been suggested to exist between
been shown to occur within 24 hours with no further IGF-I and VEGF. In vitro, IGF-I stimulated VEGF
change after 48 hours [21]. Consistently, an increase in mRNA and protein expression in human SaOS-2 osteo-
nephron filtration rate has been found after two days of blast-like cells and murine osteoblasts [31]. In a mouse
high protein intake [22]. model of proliferative retinopathy with well-characterized
Several mechanisms have been suggested to be players VEGF-dependence, administration of JB3, an IGF-I re-
in the renal effects of high protein diets. Nitric oxide has ceptor antagonist, suppressed retinal neovascularization in
been demonstrated to mediate the renal hemodynamic vivo [7]. JB3 did not reduce retinal protein/mRNA levels
effects of a high dietary protein intake (hyperfiltration of VEGF and VEGFRs nor VEGFR-2 phosphorylation,
and renal vasodilation) in rats [23]. Prostaglandin pro- but reduced the VEGF activation of the p44/42 mitogen-
duction was enhanced by dietary protein intake in rats, activated protein kinase (MAPK) pathway; MAPK be-
both in glomeruli [24] and tubuli [25], and prostaglandins ing essential for VEGF-stimulated retinal endothelial cell
are known to regulate GFR and renal plasma flow. So- growth [7]. As mentioned above, IGF-I has been impli-
dium load has been suggested to be a major factor trig- cated in high protein-induced renal growth [3]. In our
gering tubular growth after high protein intake, while study renal IGF-I protein levels were up-regulated at day 2
an increase in nephron filtration rate after high protein and day 7 in high protein fed mice. VEGF-ab administra-
intake is thought to induce glomerular growth [22]. Orni- tion affected neither serum nor kidney IGF-I levels. Ac-
thine decarboxylase (ODC) is the rate-controlling en- cordingly, our results are in concert with the hypothesis
zyme for the biosynthesis of growth regulatory poly- of an interrelation between VEGF and IGF-I with VEGF
amines [26]. A significant increase in renal ODC activity being a downstream mediator of IGF-I. However, the
is observed in rats fed a high protein diet and may be assumption that IGF-I induces glomerular hypertrophy
linked to the increase in GFR [21]. Finally, a role for through VEGF remains to be proven.
IGF-I in the induction of protein-induced renal growth In conclusion, administration of a neutralizing VEGF-ab
is strongly supported by a study in rats that found a in mice fed a high protein diet for one week completely
positive correlation between renal IGF-I gene expres- prevented the glomerular hypertrophy seen in placebo-
sion and dietary protein content [3]. treated animals on the same diet, without affecting kid-
Our results support a role for VEGF in high protein- ney or body weight. The present study, to our knowledge
induced glomerular growth. The VEGF system consists of for the first time, supports a specific role for VEGF in
a group of five different isoforms and two VEGF recep- high protein-induced glomerular growth.
tors (VEGFR-1 and VEGFR-2) [27]. VEGF and VEGF
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